Demethylwedelolactone

Demethylwedelolactone (DWL) is a coumestan, originally isolated from E. alba, with diverse biological activities.^1,2,3,4 It reduces cytotoxicity induced by CCL₄ and galactosamine (GaIN; Item No. 22981) in rat hepatocytes in a dose-dependent manner.¹ DWL inhibits trypsin with an IC₅₀ value of 3.0 μg/ml in vitro.² It is the major constituent in purified butanolic extracts of E. prostrata which inhibit lethal and hemorrhagic activities of C. rhodostoma venom.³ DWL also inhibits anchorage-independent cell growth of MDA-MB-231 breast cancer cells and decreases the number of lung metastases in an MDA-MB-231 xenograft model in nude mice.⁴

WARNING This product is not for human or veterinary use.

1. Wagner, H., Geyer, B., Kiso, Y., et al. Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Med. 5, 370-374 (1986).

2. Syed, S.D., Deepak, M., Yogisha, S., et al. Trypsin inhibitory effect of wedelolactone and demethylwedelolactone. Phytother. Res. 17(4), 420-421 (2003).

3. Pithayanukul, P., Laovachirasuwan, S., Bavovada, R., et al. Anti-venom potential of butanolic extract of Eclipta prostrata against Malayan pit viper venom. J. Ethnaopharmacol. 90(2-3), 347-352 (2004).

4. Lee, Y.-J., Lin, W.-L., Chen, N.-F., et al. Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice. Eur. J. Med. Chem. 56(1), 631-637 (2012).